3. Syngal S, Brand RE, Church JM, et al. 2015; ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 110:223–263. DOI:
10.1038/ajg.2014.435. PMID:
25645574. PMCID:
PMC4695986.
Article
5. Ribic CM, Sargent DJ, Moore MJ, et al. 2003; Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–257. DOI:
10.1056/NEJMoa022289. PMID:
12867608. PMCID:
PMC3584639.
Article
6. André T, Shiu KK, Kim TW, et al. 2020; Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 383:2207–2218. DOI:
10.1056/NEJMoa2017699. PMID:
33264544.
Article
7. Goldstein J, Tran B, Ensor J, et al. 2014; Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 25:1032–1038. DOI:
10.1093/annonc/mdu100. PMID:
24585723. PMCID:
PMC4072907.
Article
8. Battaglin F, Naseem M, Lenz HJ, Salem ME. 2018; Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 16:735–745. PMID:
30543589. PMCID:
PMC7493692.